BioScience Trends. 2020;14(5):390-395. (DOI: 10.5582/bst.2020.01048)

Methyl-CpG binding domain protein 3: a new diagnostic marker and potential therapeutic target of melanoma

Ishibashi T, Kajihara I, Mizuhashi S, Kuriyama H, Kimura T, Kanemaru H, Makino K, Miyashita A, Aoi J, MakinoT, Fukushima S, Kita K, Ihn H


Methyl-CpG binding domain protein 3 (MBD3) belongs to the methyl-CpG binding protein family. MBD3 facilitates the initiation of neural stem cell reprogramming. Melanoma originates in melanocytes derived from neural crest stem cells; therefore, we investigated the role of MBD3 in melanoma. MBD3 was overexpressed in melanoma compared with pigmented nevi. MBD3 knockdown had no effect on the proliferation of melanoma cells (A375 and A2058 cells). Contrarily, it significantly reduced the migration and invasion of A375 cells, but had no significant effect on A2058 cells. Furthermore, MBD3 knockdown reduced N-cadherin protein levels and matrix metalloproteinase-2 (MMP-2) activity in A375 cells, but had no significant effect on A2058 cells. Based on these results, the MBD3 expression level may be a useful biomarker for the diagnosis of melanoma. Thus, MBD3 has potential as a novel therapeutic target for some melanoma patients.

KEYWORDS: MBD3, melanoma, N-cadherin, MMP-2

Full Text: